Skip to content

Borderline Personality Disorder

Featured Studies

Featured studies include only those currently recruiting participants. Studies with the most recent start date appear first.

  • Isolating Mechanisms in the Treatment of Borderline Personality Disorder
    Study Type: Interventional
    Start Date: October 15, 2017
    Location: Boston, Massachusetts
    Eligibility: Ages 18 and Older, Does Not Accept Healthy Volunteers

    Borderline personality disorder (BPD) is a commonly occurring, severe, and costly condition that interferes greatly with quality of life. Considerable comorbidity with other disorders and existing multicomponent treatments with largely untested putative mechanisms of action represent obstacles for effective dissemination of BPD treatment; in light of this gap, the purpose of the present study is to isolate the effects of individual treatment components on putative mechanisms implicated in both BPD. This study will answer important theoretical questions about the mechanism of treatment change, and might lead to more efficacious, cost-effective, and easily disseminable treatment strategies for BPD, a severe and understudied disorder.

  • A Study Examining Adolescents With Non-Suicidal Self-Injury
    Study Type: Observational
    Start Date: August 1, 2016
    Location: Minneapolis, Minnesota
    Eligibility: Females, Ages 12–16, Accepts Healthy Volunteers

    This study will examine longitudinal brain development in young adolescent girls with a history of Non-Suicidal Self-Injury (NSSI). Specifically, three constructs outlined by the the Research Domains Criteria (RDoC) will be examined through self-assessment, MRI, and a cognitive battery.

  • The Staged Treatment in Early Psychosis Study
    Study Type: Interventional
    Start Date: April 1, 2016
    Locations: Glenroy, Victoria, Australia; Melbourne, Victoria, Australia
    Eligibility: Ages 12–25, Does Not Accept Healthy Volunteers

    A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical and/or functional outcomes.

  • Effectiveness of PTSD Treatment For Suicidal and Multi-Diagnostic Clients
    Study Type: Interventional
    Start Date: February 1, 2016
    Location: Seattle, Washington
    Eligibility: Ages 12 and Older, Does Not Accept Healthy Volunteers

    The present project has two primary aims: (1) to examine the effectiveness of a multi-component implementation strategy in improving adoption and adherence to the Dialectical Behavior Therapy Prolonged Exposure (DBT PE) protocol, and (2) to evaluate the feasibility, acceptability, and effectiveness of the DBT PE protocol in a sample of individuals receiving DBT in public mental health agencies. This study uses a hybrid type 2 effectiveness-implementation design to simultaneously test the clinical effectiveness of DBT + DBT PE and to evaluate an adaptive, multi-component implementation strategy. The effectiveness trial will use a quasi-experimental, controlled design to evaluate outcomes among DBT clients with PTSD who do versus do not receive the DBT PE protocol and outcomes will be benchmarked to those obtained in research settings.

  • A D1 Agonist For Working Memory
    Study Type: Interventional
    Start Date: April 1, 2013
    Location: New York, New York
    Eligibility: Ages 18–65, Accepts Healthy Volunteers

    The purpose of the study is to examine the effects of the administration of a drug called DAR-0100A on attention and memory in persons with schizotypal personality disorder (SPD). DAR-0100A has not been FDA approved, however in recent studies has been used to treat cognitive deficits, meaning problems in the way you organize your thinking, in people diagnosed with schizophrenia.

    Many people who carry a diagnosis of schizotypal personality disorder have trouble with attention and memory. Increasing the presence of a brain chemical called dopamine has been found to help people with schizophrenia with their attention and memory problems. This study will investigate whether the same is true for people with schizotypal personality disorder by using DAR-0100A, a drug that has been shown to help with the cognitive deficits of people with Parkinson's disease by increasing dopamine effects. Information collected in this experiment may lead to a better understanding of the brain mechanisms involved in schizotypal personality disorder and improve treatments for the psychological problems associated with this condition.